Avenue Therapeutics, Inc. (ATXI): Shareholders' Equity
$1.83M
As of 2025-12-31
$569.0K
As of 2026-06-30
-22.3%
3-year compound annual growth
-4.9%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.83M | -34.5% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $2.80M | +76.8% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $1.58M | -59.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $3.90M | +13.2% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $3.45M | +46.3% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $2.36M | -65.3% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $6.80M | n/m | 2021-03-31, Balance as of period end |
| 2018-12-31 | -$631.0K | n/m | 2020-03-30, Balance as of period end |
| 2017-12-31 | $19.38M | n/m | 2019-03-12, Balance as of period end |
| 2016-12-31 | -$8.25M | n/m | 2018-03-01, Balance as of period end |
| 2015-12-31 | -$5.13M | n/a | 2018-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.83M | -34.5% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$60.28M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$15.94M | n/m |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$30.15M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $6.33M | -13.5% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $35.52M | -49.5% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $33.01M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | $5.67M | -74.1% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $24.60M | +29.5% |
Compare ATXI, NWBO, NRXP, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗